IDH1 and central nervous system cancer: Although some new molecular diagnosis markers such as IDH mutation had been included in the histopathology diagnostic criteria, great intragroup survival variations exist among individual patients, such as growth status and aggressiveness of tumors, still cause huge difficulty in predicting outcome of glioma patients.